ARTICLE | Company News
Arakis, SKP joint development deal
July 16, 2001 7:00 AM UTC
SkyePharma (LSE:SKP; SKYE) and Arakis ( Cambridge, U.K.) signed a 50/50 joint deal to develop Arakis' AD313 tissue remodeling agent to treat chronic obstructive pulmonary disease (COPD), which include...